IMW 2019 | Proof-of-concept approach to overcome proteasome inhibitor resistance in myeloma
Dharminder Chauhan
• 12 Sep 2019
Dharminder Chauhan, JD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, describes a novel proof-of-concept approach to inhibit the ubiquitin proteasome pathway at the level of ubiquitin receptors and deubiquitylating enzymes, upstream of the 20S-proteasome, with a goal to block tumor growth and overcome proteasome inhibitor resistance in multiple myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
